S
Shrividya Iyer
Researcher at Pfizer
Publications - 65
Citations - 7893
Shrividya Iyer is an academic researcher from Pfizer. The author has contributed to research in topics: Palbociclib & Metastatic breast cancer. The author has an hindex of 25, co-authored 64 publications receiving 6771 citations. Previous affiliations of Shrividya Iyer include Mayo Clinic & University of Iowa.
Papers
More filters
Journal ArticleDOI
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw,Dong Wan Kim,Kazuhiko Nakagawa,Takashi Seto,Lucio Crinò,Myung-Ju Ahn,Tommaso De Pas,Benjamin Besse,Benjamin Solomon,Fiona H Blackhall,Yi-Long Wu,Michael Thomas,Kenneth J. O'Byrne,Denis Moro-Sibilot,D. Ross Camidge,Tony Mok,Vera Hirsh,Gregory J. Riely,Shrividya Iyer,V. Tassell,Anna Polli,Keith D. Wilner,Pasi A. Jänne +22 more
TL;DR: Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement and greater improvement in global quality of life with crizotinIB than with chemotherapy.
Journal ArticleDOI
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
Benjamin Solomon,Tony Mok,Dong Wan Kim,Yi-Long Wu,Kazuhiko Nakagawa,Tarek Mekhail,Enriqueta Felip,Federico Cappuzzo,Jolanda Paolini,Tiziana Usari,Shrividya Iyer,Arlene Reisman,Keith D. Wilner,Jennifer M. Tursi,Fiona H Blackhall +14 more
TL;DR: Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive NSCLC and was associated with greater reduction in lung cancer symptoms and greater improvement in quality of life.
Journal ArticleDOI
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
Hope S. Rugo,Richard S. Finn,Véronique Diéras,Johannes Ettl,Oleg Lipatov,Anil Abraham Joy,Nadia Harbeck,Aurelio Castrellon,Shrividya Iyer,D. Lu,A. Mori,Eric Gauthier,C Huang Bartlett,Karen A. Gelmon,DJ Slamon +14 more
TL;DR: These data confirm that palbociclib-letrozole should be considered the standard of care for first-line therapy in patients with ER+/HER2− ABC, including those with low disease burden or long disease-free interval, and across all patient subgroups.
Journal ArticleDOI
Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).
Dong Wan Kim,Myung-Ju Ahn,Yuankai Shi,Tommaso De Pas,Pan-Chyr Yang,Gregory J. Riely,Lucio Crinò,Tracey L. Evans,Xiaoqing Liu,Ji-Youn Han,Ravi Salgia,Denis Moro-Sibilot,Sai-Hong Ignatius Ou,Scott N. Gettinger,Yi-Long Wu,Silvana Lanzalone,Anna Polli,Shrividya Iyer,Alice T. Shaw +18 more
TL;DR: ProFILE 1005 is an ongoing global, multicenter, open-label, single-arm, phase II study evaluating the safety and efficacy of crizotinib (250 mg BID in 3-week cycles) in patients with advanced ALK-positive NSCLC who progressed after ≥1 chemotherapy for recurrent/advanced/metastatic disease.
Journal ArticleDOI
The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study
TL;DR: Symptom burden in patients with advanced NSCLC is high and has a negative impact on the quality of life, and patient-reported outcomes data could help optimize disease outcomes and therapy management inNSCLC.